Gland Pharma Q4FY26 lifts stock 16% to 52-week high

Market reaction: a sharp move on results day

Shares of Gland Pharma rallied strongly on Monday, May 18, after the company reported its financial results for the quarter and year ended March 31, 2026. The stock surged as much as 16.22% during the session to hit a 52-week high of ₹2,170 per share on the BSE. The move came as investors showed renewed preference for defensive sectors such as pharmaceuticals, while brokerages also reiterated positive views after the earnings update.

The rally put Gland Pharma in focus on Dalal Street as the counter saw brisk buying immediately after the numbers. Even after paring a part of the gains, the stock remained firmly positive through the morning. At 09:37 AM, shares were trading at ₹2,095, up 12.21% from the previous close.

Where the stock stands: price, high, and market cap

The day’s spike pushed Gland Pharma to a fresh 52-week high, with the company’s market capitalisation described as a little more than ₹35,000 crore. The stock’s longer-term performance has also been notable. Shares have gained 133% over the last three years and nearly 50% over the last one year, as per the figures cited.

The strong session also arrived amid broader investor interest in pharma stocks, often seen as relatively resilient in periods of uncertainty. That sector positioning helped sentiment, but the immediate trigger was the scale of the quarterly earnings improvement.

Q4FY26 earnings: revenue up 22%, profitability jumps

For Q4FY26, Gland Pharma reported revenue from operations of ₹1,742.8 crore, up 22% year-on-year from ₹1,424.9 crore in Q4FY25. Profitability improved sharply, with adjusted profit after tax (APAT) reported at ₹366.7 crore versus ₹186.5 crore in Q4FY25, a near doubling and about a 97% year-on-year jump.

Operating performance strengthened as well. EBITDA rose 48% year-on-year to ₹513 crore in Q4FY26 from ₹347.5 crore in the year-ago quarter. EBITDA margin for the quarter improved to 29.4%, reflecting better mix and cost actions highlighted by brokerages.

Another profitability metric also improved. Profit before tax (PBT) stood at ₹505.79 crore in Q4FY26, up 75.42% from ₹288.33 crore in Q4FY25.

Segment drivers: CDMO contribution and base business margin

A key theme in the brokerage commentary was the role of the CDMO segment in driving growth. The CDMO business contributed 25% of total revenues and grew 65% year-on-year, according to the details cited. This performance supported the broader narrative of improving growth momentum beyond the base business.

The company’s base business also saw support from product mix and cost efficiency initiatives. Those factors helped the base business achieve an adjusted EBITDA margin of 38%, as stated in the coverage. The margin and mix improvement became an important input in brokerages retaining positive ratings despite the stock’s sharp run-up.

Dividend: ₹20 per share recommended

Alongside the quarterly numbers, the board recommended a final dividend of ₹20 per equity share of face value ₹1 each for FY26. This was described as 2,000% in dividend terms. While dividend yield was not highlighted in the provided details for this announcement, the payout added to the overall shareholder return narrative on results day.

FY27 outlook: growth and margin guidance in focus

Management guidance for FY27 also featured prominently in analyst notes. The company’s topline guidance of 12% to 13% constant-currency top-line growth in FY27 was described as in line with expectations by at least one brokerage.

Margin guidance was also discussed. Ex-Cenexi EBITDA margin guidance of 33% to 35% was characterised as conservative in the cited commentary. The mention of Cenexi remained important because multiple brokerages pointed to improving profitability in that business.

Brokerage views: Elara and Motilal Oswal reiterate ‘Buy’

Brokerage commentary added fuel to the rally, with Elara Capital and Motilal Oswal Financial Services (MOFSL) retaining Buy ratings. Elara Capital cited improving growth momentum, strong product launches, and margin expansion. It retained a Buy call and raised its target price to ₹2,306 from ₹2,225, valuing the business on 25x FY28E core EPS plus cash per share.

MOFSL also reaffirmed its Buy rating, highlighting robust earnings, record core-market revenue, improving Cenexi profitability, and growth potential from CDMO and GLP-1 opportunities. The brokerage said the company delivered a better-than-expected performance, with an 8% revenue beat, 25% EBITDA beat, and 40% PAT beat for the quarter, marking the second consecutive earnings beat.

MOFSL raised its earnings estimates by 8% to 10% for FY27 and FY28, citing product launches in core markets, improving profitability of the Cenexi business, and currency depreciation tailwinds. It expects a 19% earnings CAGR over FY26-28, driven by a complex injectable pipeline, and set a target price of ₹2,300 based on 27x 12-month forward earnings.

Valuation references and implied upside after the rally

With the stock touching ₹2,170 intraday, brokerages also framed the remaining upside as modest but present. Elara noted that Gland Pharma trades at 25x FY27E core P/E and that its target implies an upside of 6.3% from the day’s intraday high levels. MOFSL similarly indicated its target price implies nearly 6% upside from the intraday high.

These valuation markers mattered because the stock had already moved sharply during the session. The post-results reaction, therefore, reflected both earnings strength and the market’s willingness to pay up for visibility on launches and margins.

Key numbers at a glance

Brokerage targets and assumptions cited

Market impact: why the quarter mattered to investors

The scale of improvement in profitability was central to the market reaction, particularly the near doubling in APAT and the sharp rise in EBITDA. The better margins, along with commentary around product mix and cost initiatives, addressed a key investor question on sustainability of operating performance.

The CDMO segment’s growth, combined with stated contribution to overall revenue, also added a clearer growth lever for investors to track. And with management indicating 12% to 13% constant-currency growth guidance for FY27, the market had a forward reference point beyond the quarter.

What to watch next

Going forward, investor focus is likely to remain on execution against FY27 growth guidance, margins excluding Cenexi, and the pace of product launches in core markets as cited by brokerages. Commentary around Cenexi profitability and any incremental momentum in CDMO will also stay relevant, given how prominently both featured in analyst notes.

Conclusion

Gland Pharma’s stock hit a 52-week high after Q4FY26 results showed a 22% rise in revenue, a sharp jump in APAT, and stronger margins. With Elara and MOFSL retaining Buy ratings and targets around ₹2,300 to ₹2,306, the next key markers will be FY27 growth delivery and margin trajectory guided by management.